There are only 14 days left until the 58th Annual Meeting & Exposition of the American Society of Hematology (ASH).
For over 50 years, the ASH annual meeting has been considered the premier event for the exchange of scientific knowledge, specifically in the field of malignant and non-malignant hematology. This event is typically attended by more than 20,000 hematology professionals, from every speciality, and from across the globe making it the perfect opportunity to network with the top minds in the field. Each year, ASH receive over 5,000 abstracts for this event, of which over 3,000 pass the extensive peer review process and are accepted for poster and oral presentations. The highlight of the event is considered to be the Plenary Scientific Session where the top 6 abstracts, selected by the Program Committee, are presented and discussed.
The Lymphoma Hub had a fantastic few days reporting live from ASH 2015, held in Orlando. We had the opportunity to see a number of exciting abstract presentations which we reported and tweeted live each day. Exciting advancements in Lymphoma and Chronic Lymphocytic Leukemia presented in oral and poster abstract sessions at last year’s event included:
- Novel immunotherapy strategies in Lymphoma
- Biology of Hodgkin Lymphoma
- New drugs in non-Hodgkin Lymphoma
- Upfront therapy in Chronic Lymphocytic Leukemia
- Response-adapted therapy and new combinations in Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma – Beyond R-CHOP
In addition, at last year’s event, the Lymphoma Hub interviewed top experts in the field of malignant hematology; we discussed results of the MCL3001 trial with Simon Rule, we speculated on the future role of R-CHOP for patients with Lymphoma with Jason Westin, and we asked Nathan Fowler his opinion on how ibrutinib could change the treatment and management of patients with Follicular Lymphoma.
This year’s ASH Annual Meeting & Exposition is taking place at the San Diego Convention Center, California, from 3–6 December, and the Lymphoma Hub will be there. Be sure to visit the Lymphoma Hub for coverage of oral abstracts, educational sessions, and interviews with speakers and our Steering Committee members.